
Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Articles by Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Advertisement
Latest Updated Articles
- Abstract Recap: Cost-Effectiveness and Budget Impact of Tildrakizumab for First-Line Treatment of Plaque Psoriasis
Published: December 6th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Sexual Dysfunction From Cancer Is Widespread—and Many Don’t Know That Before Treatment, Data Show
3
Network Disconnection, Not Lesion Volume, Drives MS Cognition
4
Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD
5